Shares of Emcure Pharmaceuticals fell nearly 2% to ₹1,258.40 on Thursday after CNBC-TV18 reports emerged that Bain Capital (via BC Investments) plans to sell approximately 45.5 lakh shares, representing about 2.4% of equity, through a block deal.
According to reports, the offer price has been set at ₹1,225 per share, implying a roughly 4% discount to the previous closing price. The total deal size is expected to be about ₹551 crore. The lock-in period for the remaining stake is reportedly 90 days, with Kotak Securities acting as the banker to the transaction.
The stock traded in a day range of ₹1,250–₹1,282 on NSE, compared to its previous close of ₹1,279.80.
This divestment marks another stake sale by Bain Capital, which has gradually been paring down its holding in the pharmaceutical company since its listing.
Market Cap: ₹242.6 billion
P/E Ratio: 35.09
52-Week Range: ₹889 – ₹1,580
Investors are watching closely how the market absorbs this supply of shares and whether the stock stabilizes after the block deal.
